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of 5 FACT accredited HCTP, analyzed Medicare claims data
submitted by SCBCN between 1/1/11 and 12/31/11. 120 HCT
were performed on 119 patients (pts): 69 men and 50
women, median age 67 years (range 28-79) with Multiple
Myeloma (62), Lymphoma (35), Acute Leukemia (17) and
other (5). There were 23 allogeneic (allo) HCT (MS-DRG-14),
2 of which were outpatient with an average length of stay
(LOS) of 30 days (0-123) for related and 25 days (5-55) for
unrelated; 12/23 were < 20 days. Inpatient coding for
autologous (auto) HCT was split among three MS-DRG
because of a change in 2012 from MS-DRG- 15 (71) and to
MS-DRG 16dwith complication/comorbidity (cc) (18) and
MS-DRG 17dwithout cc (8) with average LOS 18 days (2-39);
55/97 were<20 days. Of 18 pts assigned DRG16, all appeared
to have codes supporting increased complexity. Of 8 pts
assigned DRG17, 5 had codes that might have supported
billing under DRG 16. Among 23 allo pts, 7 were missing the
code deﬁning donor source as related or unrelated including
both patients who received outpatient allo HCT. Revenue
code 819, which reports charges for donor cell acquisition,
was reported in 18 cases with a 40-fold variance in range of
charges. Interestingly, this code was also submitted in 46 of
97 auto cases.
Conclusion: Signiﬁcant opportunities may exist for using
the proper MS-DRG for auto pts (which has substantial
revenue implications) and the use of revenue code 819 for
allo HCT (which has substantial implications for future rate
setting). Programs can signiﬁcantly increase future
payment rates by understanding their current Medicare
billing practices and identifying opportunities for
improvement. Further investigation will focus on estima-
tion of costs as compared with reimbursement for Medi-
care beneﬁciaries.332
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Purpose: Effective training of data managers (DM) is
instrumental to assure accurate, quality data. The National
Marrow Donor Program (NMDP) and the Center for Inter-
national Blood and Marrow Transplant Research (CIBMTR)
network provide training resources and liaisons for each
transplant center in order to assist in proper completion of
the CIBMTR data collection forms. The University of Mary-
land Greenebaum Cancer Center's (UMGCC) Blood and
Marrow Transplant (BMT) team utilizes the CIBMTR elec-
tronic training resources and liaisons, as well as other alter-
native training methods. Our team was interested in
assessing the effectiveness of DM training methods and to
enhance the CIBMTR DM training model.
Method: The UMGCC BMT team developed an anonymous,
twenty-question survey on the various training methods
implemented at 138 NMDP and CIBMTR-afﬁliated transplant
centers in the U.S. The survey consisted of quantitative and
qualitative questions pertaining to demographics, prior DM
experience, and training.
Results: Seventy DMs responded to the survey. Participant
ages were well distributed with 29% of participants 18 to 34
years, 39% 35 to 49 years, and 33 % 50 to 64 years. Most
respondents (66%) reported that they had been a CIBMTR DM
for greater than 5 years. Half (51%) participated in monthly
internal assessments and 57% worked at centers thatperformed over 100 transplants per year. When asked about
training to become a DM, 51% reported having less than 1
week of training and 88% reported not being extremely
satisﬁed with his/her DM training. Thirty percent had no
previous experience with BMT-related information when
they became a DM and most (53%) were not audited prior to
independently completing CIBMTR forms. Training to
complete CIBMTR forms ranged from none to training
received from multiple sources. At the time of the survey,
54% were not familiar with the current CIBMTR training
model.
Conclusion: The CIBMTR DM Training Methods Survey
shows that CIBMTR DMs vary by age, previous experience,
and levels of training. Based on the data, it is evident that
a trainingmodel, which incorporates speciﬁc procedures and
methods, would be of value to CIBMTR DMs and the data
they report. Standardized DM training would improve the
accuracy and quality of data, which would contribute to the
knowledge learned from hematopoietic stem cell transplant
research.333
Standardizing Standard Operating Procedures' (SOP)
Manual to Benchmark Cell Processing Laboratory (CPL)
Performance
Mehboob Merchant 1, Morris Kletzel 1,2,3, Marcelo Villa 1,
Thomas Shook 1, Leo I. Gordon 1,4. 1 Cell Therapy Processing
Facility, Northwestern Memorial Hospital, Chicago, IL;
2 Northwestern University Feinberg School of Medicine,
Chicago, IL; 3 Ann & Robert H. Lurie Children's Hospital of
Chicago; 4 Northwestern Univ Medical School, Div of Hem/Onc,
Chicago, IL
Background: Healthcare SOPs are now standardized. There
are a few hundred routine CPL policies/procedures (P/P) and
maintaining SOP Manual (SOPM) becomes a daunting task.
SOP of any two labs would not only differ on how to achieve
the same task but no two SOPM would equally cover all
topics required by regulatory and/or accrediting agency
(R/AA).
Amongst the R/AA, JC, OSHA, CLIA, CAP, AABB, FACT & FDA
all have oversight claims on the lab, including lab practices
and SOPs. Failure to abide may result in catastrophic
outcome from citation to shut down and insurance
disapproval.
Objective: R/AA have common minimum standards-
patient safety is the prime concern, and it may be possible
to standardize R/AA requirements so that SOPM for every
CPL is identical in content, achieving uniformity across the
board.
Methods: In 2008, our CPL had a management change
and became an independent lab with a cGMP facility. We
inherited SOPs from two departments, a total of 161
policies plus 204 forms. There was confusion and dupli-
cation with two dissimilar SOPs and formats, also
previous P/P had not been updated to current regulatory
guidelines.
Early in 2010, we merged the two sets into integrated,
practical and regulatory-compliant documents with novel
formatting to distinguish one from the others. FDA regula-
tions took precedence over other R/AA.
FDA, FACT, CAP and the JC's guidelines were keenly
scrutinized prior to addressing the merger. SOPs were sorted
into three broad categories: Quality Management, Cell Pro-
cessing and cGMP.
